Initial Patient Characteristics Associated With Ineligibility for Second‐Line Therapy After Progression on First‐Line Osimertinib in EGFR‐Mutated Non‐Small Cell Lung Cancer

ABSTRACT Background Osimertinib, an irreversible third‐generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI), improves survival in patients with EGFR‐mutated non‐small‐cell lung cancer (NSCLC). However, a substantial proportion of patients do not proceed to subsequent ther...

Полное описание

Библиографические подробности

Главные авторы:	Hiroaki Kodama, Haruyasu Murakami, Nobuaki Mamesaya, Haruki Kobayashi, Kazushige Wakuda, Ryo Ko, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Tetsuo Shimizu, Yasuhiro Gon, Toshiaki Takahashi
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Wiley 2025-11-01
Серии:	Thoracic Cancer
Предметы:	CNS metastasis EGFR‐TKI NSCLC older patients osimertinib
Online-ссылка:	https://doi.org/10.1111/1759-7714.70192
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!